Poland's Mabion aims to produce Novavax vaccine for Europe from Q3
The Peninsula
WARSAW: Poland's Mabion aims to start production of U.S. firm Novavax's coronavirus vaccine for Europe from the third quarter, representatives of the biotechnology company said.
Mabion and Novavax last month signed a framework deal on the transfer of COVID-19 vaccine technology to Mabion's plant in central Poland, which was designed to produce a rare diseases drug yet to be registered. "The production of our core product is much more complicated (than vaccine)," Mabion board member Adam Pietruszkiewicz told Reuters.More Related News